Novartis stretches Leqvio data beyond six years

Swiss pharma giant Novartis (NOVN: VX) has announced new long-term data from the ORION-8 Phase III open-label extension.

These results show the continued efficacy and safety of Leqvio (inclisiran), the company’s on-market cholesterol-lowering therapy. It is the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C) and is approved in more than 80 countries, including the USA, European Union and China.

"The ORION-8 results affirm the benefits of Leqvio in helping patients achieve sustained LDL-C reduction"The data demonstrated that with twice-yearly dosing, Leqvio, in addition to statin therapy, provides consistent LDL-C reduction beyond six years in patients with atherosclerotic cardiovascular disease (ASCVD), increased risk of ASCVD or heterozygous familial hypercholesterolemia.